BMP6 and chronic kidney disease: The BMP6-neutralizing drug has been evaluated for safety and pharmacokinetics in two phase 1 clinical trials with healthy volunteers and CKD patients (ClinicalTrials.gov Identifiers: NCT02144285 and NCT02604160).